Clinical trial
A Phase 1, Randomized, Double-blind, Single-and Multiple-dose Escalation, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of QLS1128 and in Combination With Ritonavir in Healthy Participants
NCT05458076 is registered in ClinicalTrials.gov with Qilu Pharmaceutical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Randomized, Double-blind, Single-and Multiple-dose Escalation, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of QLS1128 and in Combination With Ritonavir in Healthy Participants
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- July 3, 2022
- Completion date
- September 6, 2022
- Enrollment
- 86 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.